Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI)

TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology from February 23 - 27, 2007 in San Diego, CA. The posters discussed findings from a survey of 202 otolaryngologists (ENTs) and allergists in the U.S., U.K., France, and Germany on the burden of chronic sinusitis (CS), the knowledge and attitudes of the fungal etiology of CS, and the differences in treatment practices of CS in the U.S. and Europe.